Neuropeptidni Y receptor
| Neuropeptidni Y receptor Y1 | |
|---|---|
| Identifikatori | |
| Simbol | NPY1R |
| Alt. simboli | NPYR |
| Entrez | 4886 |
| HUGO | 7956 |
| OMIM | 162641 |
| RefSeq | NM_000909 |
| UniProt | P25929 |
| Drugi podaci | |
| Lokus | Hromozom 4 q31.3-q32 |
| Neuropeptidni Y receptor Y2 | |
|---|---|
| Identifikatori | |
| Simbol | NPY2R |
| Entrez | 4887 |
| HUGO | 7957 |
| OMIM | 162642 |
| RefSeq | NM_000910 |
| UniProt | P49146 |
| Drugi podaci | |
| Lokus | Hromozom 4 q31 |
| Pankreasni polipeptidni receptor 1 | |
|---|---|
| Identifikatori | |
| Simbol | PPYR1 |
| Alt. simboli | NPY4R, Y4, PP1 |
| Entrez | 5540 |
| HUGO | 9329 |
| OMIM | 601790 |
| RefSeq | NM_005972 |
| UniProt | P50391 |
| Drugi podaci | |
| Lokus | Hromozom 10 q11.2 |
| Neuropeptidni Y receptor Y5 | |
|---|---|
| Identifikatori | |
| Simbol | NPY5R |
| Entrez | 4889 |
| HUGO | 7958 |
| OMIM | 602001 |
| RefSeq | NM_006174 |
| UniProt | Q15761 |
| Drugi podaci | |
| Lokus | Hromozom 4 q31-q32 |
Neuropeptidni Y receptori su klasa G-protein spregnutih receptora koje aktiviraju peptidni hormoni neuropeptid Y, peptid YY i pankreasni polipeptid.[1] Ovi receptori učestvuju u kontroli raznovrsnog seta of procesa ponašanja, koji obuhvata apetit, cirkadijalni ritam, i anksioznost.[2][3][4][5][6][7]
Aktivirani neuropeptidni receptori oslobađaju Gi podjedinicu iz heterotrimernog G proteinskog kompleksa. Gi podjedinica zatim inhibira produkciju sekundarnog glasnika cAMP iz ATP.
Poznata su četiri neuropeptid Y receptora kod sisara. Oni se označavaju sa: Y1 do Y5.[8] Svaki od ovih receptora je kodiran zasebnim genom kod čoveka. Svi oni mogu da budu terapeutski ciljevi za gojaznost i druge poremećaje.[9][10][11]
- ↑ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.[mrtav link]
- ↑ Heilig M (August 2004). „The NPY system in stress, anxiety and depression”. Neuropeptides 38 (4): 213–24. DOI:10.1016/j.npep.2004.05.002. PMID 15337373.
- ↑ Harro J (October 2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids 31 (3): 215–30. DOI:10.1007/s00726-006-0334-x. PMID 16738800.
- ↑ Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry 7 (17): 1645–59. DOI:10.2174/156802607782341037. PMID 17979774.[mrtav link]
- ↑ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery 1 (3): 315–24. DOI:10.2174/157488906778773689. PMID 18221213.[mrtav link]
- ↑ Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.
- ↑ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. DOI:10.1016/j.nut.2008.06.025. PMID 18725086.
- ↑ Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides 38 (4): 141–51. DOI:10.1016/j.npep.2004.06.002. PMID 15337367.
- ↑ Kamiji MM, Inui A (October 2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews 28 (6): 664–84. DOI:10.1210/er.2007-0003. PMID 17785427.
- ↑ MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.
- ↑ Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.
- „Neuropeptide Y Receptors”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Arhivirano iz originala na datum 2016-03-03.
- MeSH Neuropeptide+Y+Receptor